<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03154047</url>
  </required_header>
  <id_info>
    <org_study_id>NEOD001-OLE251</org_study_id>
    <nct_id>NCT03154047</nct_id>
  </id_info>
  <brief_title>Study in Subjects With Light Chain (AL) Amyloidosis</brief_title>
  <official_title>A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Who Were Previously Enrolled in Study NEOD001-201 (PRONTO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prothena Therapeutics Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prothena Therapeutics Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the long-term safety and efficacy of NEOD001 in
      subjects with AL amyloidosis who have completed Study NEOD001-201.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Global, multicenter, Phase 2b, open-label extension study of subjects with AL amyloidosis who
      had a hematologic response to first-line treatment for their amyloidosis (e.g., chemotherapy,
      autologous stem cell transplant [ASCT]) and completed Study NEOD001-201. Subjects in this
      study may receive concomitant chemotherapy. Subject screening will occur during the 28 days
      prior to the first administration of study drug, which may overlap with the last visit in
      Study NEOD001-201. If all eligibility requirements are met, the subject will be enrolled and
      Screening assessments will be completed. Study visits will occur every 28 days based on
      scheduling from Month 1 Day 1. A ±5-day window is allowed for visits starting after Month 1.
      Subjects who discontinue study drug before the End of Study Visit (EOS) should have an Early
      Treatment Discontinuation Visit 30 (±5) days after their final administration of study drug.
      Each subject's study participation may be up to 38 months or until the study is terminated,
      whichever occurs first. The study consists of a Screening Phase (1 month), Treatment Phase
      (36 months), and EOS Visit (30 [±5] days after the last dose).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Long term safety and tolerability as assessed by vital signs, 12-lead ECGs, routine clinical laboratory assessments, and Adverse Events</measure>
    <time_frame>baseline up to 38 months</time_frame>
    <description>Safety will be assessed through changes in vital signs, 12-lead ECGs, laboratory test results, and summaries of AEs. All TEAEs and SAEs will be summarized.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac best response as measured by NT-proBNP</measure>
    <time_frame>baseline up to 38 months</time_frame>
    <description>Response rates will be summarized including 95% confidence intervals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Form-36 (SF-36) questionnaire</measure>
    <time_frame>baseline up to 38 months</time_frame>
    <description>Change from baseline will be analyzed using linear mixed model for repeated measurements (MMRM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 6MWT</measure>
    <time_frame>baseline up to 38 months</time_frame>
    <description>The 6 MWT distance change from baseline will be analyzed using a Wilcoxon signed rank test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal best response rate as measured by proteinuria</measure>
    <time_frame>baseline up to 38 months</time_frame>
    <description>Response rates will be summarized including 95% confidence intervals. The distributions of time-to-event endpoints will be summarized using the Kaplan-Meier method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Neuropathy Impairment Score-Lower Limbs (NIS-LL) total score</measure>
    <time_frame>baseline up to 38 months</time_frame>
    <description>Change from baseline in NIS-LL will be summarized including 95% confidence intervals. The distributions of time-to-event endpoints will be summarized using the Kaplan-Meier method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic response</measure>
    <time_frame>baseline up to 38 months</time_frame>
    <description>Response rates will be summarized including 95% confidence intervals</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>AL Amyloidosis</condition>
  <arm_group>
    <arm_group_label>Open label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open Label Study Drug NEOD001</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NEOD001</intervention_name>
    <description>humanized monoclonal antibody</description>
    <arm_group_label>Open label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Completed the End of Study Visit in Study NEOD001-201

          2. Adequate bone marrow reserve, hepatic and renal function, as demonstrated by:

               -  Absolute neutrophil count (ANC) ≥1.0 × 109/L

               -  Platelet count ≥75 × 109/L

               -  Hemoglobin ≥9 g/dL

               -  Total bilirubin ≤2 × upper limit of normal (ULN)

               -  Aspartate aminotransferase (AST) ≤3 × ULN

               -  Alanine aminotransferase (ALT) ≤3 × ULN

               -  Alkaline phosphatase (ALP) ≤5 × ULN (except for subjects with hepatomegaly and
                  isozymes specific to liver, rather than bone)

               -  Estimated glomerular filtration rate (eGFR) ≥25 mL/min/1.73 m2 as estimated by
                  the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, or
                  measured GFR ≥25 mL/min/1.73 m2

          3. Systolic blood pressure 80-180 mmHg

          4. Women of childbearing potential must have a negative pregnancy test during Screening
             and must agree to use highly effective physician-approved contraception from Screening
             to 90 days following the last study drug administration

          5. Male subjects must be surgically sterile or must agree to use highly effective
             physician-approved contraception from Screening to 90 days following the last study
             drug administration

          6. Ability to understand and willingness to sign an informed consent form prior to
             initiation of any study procedures

        Exclusion Criteria:

          1. Any new medical contraindication or clinically significant abnormality on physical,
             neurological, laboratory, vital signs, or electrocardiographic (ECG) examination
             (e.g., atrial fibrillation; with the exception of subjects for whom the ventricular
             rate is controlled) that precludes continuation or initiation of treatment with
             NEOD001 or participation in the study

          2. Symptomatic orthostatic hypotension that in the medical judgment of the Investigator
             would interfere with subject's ability to safely receive treatment or complete study
             assessments

          3. Myocardial infarction, uncontrolled angina, uncontrolled ventricular arrhythmias, or
             ECG evidence of acute ischemia, within 6 months prior to the Month 1-Day 1 Visit

          4. Severe valvular stenosis (e.g., aortic or mitral stenosis with a valve area &lt;1.0 cm2)
             or severe congenital heart disease

          5. ECG evidence of acute ischemia or active conduction system abnormalities with the
             exception of any of the following:

               -  First degree atrioventricular (AV) block

               -  Second degree AV block Type 1 (Mobitz Type 1/ Wenckebach type)

               -  Right or left bundle branch block

               -  Atrial fibrillation with a controlled ventricular rate (uncontrolled [i.e., &gt;110
                  bpm] ventricular rate is not allowed [determined by an average of three beats in
                  Lead II or 3 representative beats if Lead II is not representative of the overall
                  ECG])

          6. Has not recovered (i.e., equivalent to a Common Terminology Criteria for Adverse
             Events [CTCAE] ≥Grade 2) from the clinically significant toxic effects of prior
             anticancer therapy. Exception: subjects who have received treatment with a proteasome
             inhibitor such as bortezomib may have CTCAE Grade 2 neuropathy.

          7. Received any of the following within the specified time frame prior to the Month 1-Day
             1 Visit:

               -  Oral or IV antibiotics, antifungals, or antivirals within 1 week, with the
                  exception of prophylactic oral agents. Note: In the event that a subject requires
                  the chronic use of antivirals, Medical Monitor permission is required for entry
                  into the study.

               -  Hematopoietic growth factors, transfusions of blood or blood products within 1
                  week

               -  Chemotherapy, radiotherapy, HDAC inhibitors, or other plasma cell directed
                  therapy within 2 weeks

               -  ASCT within 4 weeks (i.e., ASCT is allowed if it occurred before enrollment in
                  Study NEOD001-201 or after completion of Study NEOD001-201 if it was at least 4
                  weeks before Month 1-Day 1 of this study)

               -  Major surgery within 4 weeks (or within 2 weeks following consultation with and
                  approval of Medical Monitor)

               -  Planned organ transplant during the study

               -  Any investigational agent, other than NEOD001, within 4 weeks

               -  Any experimental imaging agent directed at amyloid within 2 weeks

          8. Active malignancy with the exception of any of the following:

               -  Adequately treated basal cell carcinoma, squamous cell carcinoma, or in situ
                  cervical cancer

               -  Adequately treated Stage I cancer from which the subject is currently in
                  remission and has been in remission for ≥2 years

               -  Low-risk prostate cancer with Gleason score &lt;7 and prostate-specific antigen &lt;10
                  mg/mL

               -  Any other cancer from which the subject has been disease-free for ≥2 years

          9. History of Grade ≥3 infusion-related adverse events (AEs) or hypersensitivity to
             NEOD001

         10. History of severe allergy to any of the components of NEOD001 such as
             histidine/L-Histidine, Trehalose, or Polysorbate 20

         11. Currently known uncontrolled bacterial, viral, fungal, HIV, hepatitis B, or hepatitis
             C infection

         12. Women who are breastfeeding

         13. Any condition which could interfere with, or the treatment for which might interfere
             with, the conduct of the study or which would, in the opinion of the Investigator,
             unacceptably increase the subject's risk by participating in the study

         14. Unable or unwilling to adhere to the study-specified procedures and restrictions

         15. Subject is under legal custodianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lupe Duarte</last_name>
      <phone>626-256-4673</phone>
      <email>lduarte@coh.org</email>
    </contact>
    <investigator>
      <last_name>Michael Rosenzweig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Younger</last_name>
      <phone>720-754-4892</phone>
      <email>Leslie.Younger@healthonecares.com</email>
    </contact>
    <investigator>
      <last_name>Tara Gregory, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Hospital - Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office</last_name>
      <phone>855-776-0015</phone>
      <email>burke.kathleen@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Taimur Sher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathryn McDonnell</last_name>
      <phone>773-702-1835</phone>
      <email>kmcdonnell@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Andrzej Jakubowiak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafat Abonour</last_name>
      <phone>317-274-0843</phone>
      <phone_ext>2788</phone_ext>
      <email>rabonour@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Rafat Abonour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Mensing</last_name>
      <phone>339-222-9307</phone>
      <email>gmensing@tuftsmedicalcenter.org</email>
    </contact>
    <investigator>
      <last_name>Raymond Comenzo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christy Houde</last_name>
      <phone>313-576-9381</phone>
      <email>houdec@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Zonder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Minnesota</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morie Gertz</last_name>
      <phone>507-284-2511</phone>
      <email>gertz.morie@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Morie Gertz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Mocodeanu</last_name>
      <phone>646-888-8581</phone>
      <email>mocodeal@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Heather Landau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roslyn Lewis</last_name>
      <phone>919-688-5579</phone>
      <email>roslyn.lewis@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Cristina Gasparetto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Hirsch</last_name>
      <phone>216-444-4432</phone>
      <email>HIRSCHS3@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Jason Valent, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miranda Gordon</last_name>
      <phone>503-494-2927</phone>
      <email>gordonmi@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Heitner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Diacznysky</last_name>
      <phone>215-662-3173</phone>
      <email>ynthia.diaczynsky@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Adam Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Violeta Vartic</last_name>
      <phone>615-343-1467</phone>
      <email>violeta.vartic@Vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Stacey Goodman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Morphey</last_name>
      <phone>713-792-8785</phone>
      <email>ALandry1@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Hans Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita D'Souza</last_name>
      <phone>414-805-1826</phone>
      <email>Anitadsouza@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Anita D'Souza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiona Kwok</last_name>
      <phone>9845 6276</phone>
      <email>fiona.kwok@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Fiona Kwok, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Mollee</last_name>
      <phone>+61 7 3176 6739</phone>
      <email>peter_mollee@health.qld.gov.au</email>
    </contact>
    <investigator>
      <last_name>Peter Mollee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastern Health (Box Hill Hospital)</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Gibbs</last_name>
      <phone>+613 9094 9502</phone>
      <email>simon.gibbs@monash.edu</email>
    </contact>
    <investigator>
      <last_name>Simon Gibbs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ursula Schäff</last_name>
      <phone>+43 1 40400 44325</phone>
      <email>ursula.schaeff@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Hermine Agis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Dupuytren - CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David LAVERGNE</last_name>
      <phone>+335 55 05 86 37</phone>
      <email>david.lavergne@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Arnaud Jaccard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kahina Raab</last_name>
      <phone>+33-142-162330</phone>
      <email>kahina.cherifi@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Sylvain Choquet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anja Ullrich-Noss</last_name>
      <phone>+49 30 450513512</phone>
      <email>anja.ullrich-noss@charite.de</email>
    </contact>
    <investigator>
      <last_name>Axel Nogai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Duisburg-Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christiane Kuhnert</last_name>
      <phone>0114920723255</phone>
      <email>christiane.kuhnert@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Alexander Carpinteiro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf (UKE)</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Kühne</last_name>
      <phone>+49 (0) 40-7410-54353</phone>
      <email>p.kuehne@uke.de</email>
    </contact>
    <investigator>
      <last_name>Mascha Binder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Michel</last_name>
      <phone>+49 6221567805</phone>
      <email>Florian.Michel@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Stefan Schönland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alexandra General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Efstathios Kastritis</last_name>
      <phone>011302132162846</phone>
      <email>ekastritis@gmail.com; ekastritis@med.uoa.gr</email>
    </contact>
    <investigator>
      <last_name>Efstathios Kastritis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Patras</name>
      <address>
        <city>Patras</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vassiliki Zafeiropoulou</last_name>
      <email>vickzafirop@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Anargyros Symeonidis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center (HMC)</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moshe Gatt</last_name>
      <phone>+972-2-6779268</phone>
      <email>rmoshg@hadassah.org.il</email>
    </contact>
    <investigator>
      <last_name>Moshe Gatt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Carnevale Baraglia</last_name>
      <phone>+39 0382-502982</phone>
      <email>A.CarnevaleBaraglia@smatteo.pv.it</email>
    </contact>
    <investigator>
      <last_name>Giampaolo Merlini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio de la Riva</last_name>
      <phone>00 34 932279214</phone>
      <email>delariva@clinic.ub.es</email>
    </contact>
    <investigator>
      <last_name>Joan Blade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro - Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Krsnik</last_name>
      <phone>01134911917913</phone>
      <email>isabel.krsnik@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Isabel Krsnik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B15 2GW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hayley Ellis</last_name>
      <phone>0121 371 4351</phone>
      <email>Hayley.Ellis@uhb.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Guy Pratt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Free Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Herlihy</last_name>
      <phone>+44(0)2077940500</phone>
      <phone_ext>38229</phone_ext>
      <email>robert.herlihy@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Ashutosh Wechalekar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2017</study_first_submitted>
  <study_first_submitted_qc>May 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2017</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

